sorafenib has been researched along with fg 9041 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (fg 9041) | Trials (fg 9041) | Recent Studies (post-2010) (fg 9041) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 812 | 0 | 122 |
| Protein | Taxonomy | sorafenib (IC50) | fg 9041 (IC50) |
|---|---|---|---|
| Chain A, GLUTAMATE RECEPTOR SUBUNIT 2 | Rattus norvegicus (Norway rat) | 0.998 | |
| Chain A, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.998 | |
| Chain B, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.998 | |
| fatty acid synthase | Homo sapiens (human) | 7.755 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor 1 | Homo sapiens (human) | 1.51 | |
| Glutamate receptor 2 | Homo sapiens (human) | 1.51 | |
| Glutamate receptor 3 | Homo sapiens (human) | 1.51 | |
| Glutamate receptor 4 | Homo sapiens (human) | 1.51 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 5.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Jiang, X; Wu, K; Zhang, P; Zhang, Y | 1 |
1 review(s) available for sorafenib and fg 9041
| Article | Year |
|---|---|
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
Topics: Animals; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Antiviral Agents; Drug Development; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Mice; Neuroprotective Agents; Photochemotherapy; Quinoxalines; Structure-Activity Relationship; Tubulin Modulators | 2022 |